Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production
Diabetologia · 2023
DOI: 10.1007/s00125-023-05967-8 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetologia, 2023. Verfasst von Yael Riahi und 14 weiteren Autor:innen. Beteiligte Einrichtung: Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Experimental, Hyperglycemia. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 54 Literaturangaben. Gefördert von: BLRD VA, NIDDK NIH HHS, Israel Science Foundation.
Themen: Diabetes mellitus
Abstract (Originalsprache)
AIM/HYPOTHESIS: Hyperglycaemia is associated with alpha cell dysfunction, leading to dysregulated glucagon secretion in type 1 and type 2 diabetes; however, the mechanisms involved are still elusive. The nutrient sensor mammalian target of rapamycin complex 1 (mTORC1) plays a major role in the maintenance of alpha cell mass and function. We studied the regulation of alpha cell mTORC1 by nutrients and its role in the development of hyperglucagonaemia in diabetes. METHODS: Alpha cell mTORC1 activity was assessed by immunostaining for phosphorylation of its downstream target, the ribosomal protein S6, and glucagon, followed by confocal microscopy on pancreatic sections and flow cytometry on dispersed human and mouse islets and the alpha cell line, αTC1-6. Metabolomics and metabolic flux were studied by 13C glucose labelling in 2.8 or 16.7 mmol/l glucose followed by LC-MS analysis. To study the role of mTORC1 in mediating hyperglucagonaemia in diabetes, we generated an inducible alpha cell-specific Rptor knockout in the Akita mouse model of diabetes and tested the effects on glucose tolerance by IPGTT and on glucagon secretion. RESULTS: mTORC1 activity was increased in alpha cells from diabetic Akita mice in parallel to the development of hyperglycaemia and hyperglucagonaemia (two- to eightfold increase). Acute exposure of mouse and human islets to amino acids stimulated alpha cell mTORC1 (3.5-fold increase), whereas high glucose concentrations inhibited mTORC1 (1.4-fold decrease). The mTORC1 response to glucose was abolished in human and mouse diabetic alpha cells following prolonged islet exposure to high glucose levels, resulting in sustained activation of mTORC1, along with increased glucagon secretion. Metabolomics and metabolic flux analysis showed that exposure to high glucose levels enhanced glycolysis, glucose oxidation and the synthesis of glucose-derived amino acids. In addition, chronic exposure to high glucose levels increased the expression of Slc7a2 and Slc38a4, which encode amino acid transporters, as well as the levels of branched-chain amino acids and methionine cycle metabolites (~1.3-fold increase for both). Finally, conditional Rptor knockout in alpha cells from adult diabetic mice inhibited mTORC1, thereby inhibiting glucagon secretion (~sixfold decrease) and improving diabetes, despite persistent insulin deficiency. CONCLUSIONS/INTERPRETATION: Alpha cell exposure to hyperglycaemia enhances amino acid synthesis and transport, resulting in sustained activation of mTORC1, thereby increasing glucagon secretion. mTORC1 therefore plays a major role in mediating alpha cell dysfunction in diabetes. DATA AVAILABILITY: All sequencing data are available from the Gene Expression Omnibus (GEO) repository (accession no. GSE154126; https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE154126 ).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Diabetes Unit, Department of Endocrinology and Metabolism, Faculty of Medicine, Hebrew University of Jerusalem, Jerusalem, Israel.
- Laboratory for Metabolism in Health and Disease, Ruth and Bruce Rappaport Faculty of Medicine, Technion-Israel Institute of Technology, Haifa, Israel.
- The Azrieli Faculty of Medicine, Bar-Ilan University, Safed, Israel.
- Department of Developmental Biology and Cancer Research, Hadassah Medical Center, Hebrew University of Jerusalem, Jerusalem, Israel.
- Department of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
- Department of Biochemistry, Food Science and Nutrition, Robert H. Smith Faculty of Agriculture, Food and Environment, Hebrew University of Jerusalem, Rehovot, Israel.
Förderung
- BLRD VA
- NIDDK NIH HHS
- Israel Science Foundation
- National Institutes of Health
Zitieren
APA
Riahi, Y., Kogot-Levin, A., Kadosh, L., Agranovich, B., Malka, A., Assa, M., Piran, R., Avrahami, D., Glaser, B., Gottlieb, E., Jackson, F., Cerasi, E., Bernal-Mizrachi, E., Helman, A., & Leibowitz, G. (2023). Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production. Diabetologia. https://doi.org/10.1007/s00125-023-05967-8
Vancouver
Riahi Y, Kogot-Levin A, Kadosh L, Agranovich B, Malka A, Assa M, et al. Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production. Diabetologia. 2023. doi:10.1007/s00125-023-05967-8
BibTeX
@article{Riahi2023,
author = {Riahi, Yael and Kogot-Levin, Aviram and Kadosh, Liat and Agranovich, Bella and Malka, Assaf and Assa, Michael and Piran, Ron and Avrahami, Dana and Glaser, Benjamin and Gottlieb, Eyal and Jackson, Fields and Cerasi, Erol and Bernal-Mizrachi, Ernesto and Helman, Aharon and Leibowitz, Gil},
title = {Hyperglucagonaemia in diabetes: altered amino acid metabolism triggers mTORC1 activation, which drives glucagon production},
journal = {Diabetologia},
year = {2023},
doi = {10.1007/s00125-023-05967-8}
}
EUVIMED